Science begins to add weight to CLA
growing body of research to support the ingredient, particularly
for its effects on weight loss, potentially one of its most
profitable uses in the functional foods market.
The flurry of activity in CLA applications is being backed by a growing body of research to support the ingredient, particularly for its effects on weight loss.
A review published in this month's Journal of Nutrition supports conjugated linoleic acid's action on weight management, concluding that it is at least in part due to regulation of glucose and fatty acid uptake and metabolism.
Conjugated linoleic acid is the common name of a group of fatty acids found in dairy products and meat. CLA isomers have been studied for their action on an impressive range of diseases, including cancer, atherosclerosis, obesity, and immune function. However as scientists begin to reveal their effects on reduction of body fat, food makers are increasingly looking at the ingredient for the valuable slimming market.
In Canada, where many of the patents for CLA are held, the dairy industry has long been studying the production of high-CLA milk. In Europe, a research centre in Ireland is studying the compound which could add siginificant value to its dairy industry, while in Italy, Techno Foods introduced a strawberry flavoured yoghurt naturally rich in CLA (conjugated linoleic acid) and omega-3 fatty acids this summer.
Specific CLA isomers have been shown to prevent the development of obesity in certain rodent and pig models and this has been attributed mainly to trans-10, cis-12 CLA, both in vivo and in vitro, write the University of North Carolina researchers in the review. However, CLA's ability to modulate human obesity remains controversial because data from clinical trials using mixed isomers are conflicting.
In vitro studies by the team demonstrated that while trans-10, cis-12 CLA prevents triglyceride accumulation in human cells, cis-9, trans-11 CLA increases triglyceride content. The team concluded that the isomers' regulation of glucose and metabolism must partly explain its mechanism on human fat.
The news is also good for supplement marketers who recently learned of research carried out by Cognis backing the long-term safety of its Tonalin CLA.
